Heres commentary from Lily management: There's no doubt in my mind, Geoff in five years, as I said, we're going to have a lot more data and we're going to see these drugs as foundational medical treatment for many chronic diseases, and with outcomes to hard outcomes data that moves the cost curve in populations. And eventually the Venn diagram of seniors who have obesity or overweight and other conditions, diabetes, of course already we have access in many plans there, but we'll be adding to that pie
Direct Cellular Access : Once in your bloodstream, glutathione rapidly enters liver cells through specialized transport proteins
macrophages and DCs (IL-12 is not produced by B cells)
So its easier and cheaper to distribute the orals. Novo, for its part, is playing a different game, trying to win on model, not just on molecule, by locking in patients with pricing, distribution and familiarity before the market fragments
C4 Ultimate l dng C4 mnh nht ca Cellucor